Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Declines By 24.9%

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a large decline in short interest in December. As of December 15th, there was short interest totalling 16,900 shares, a decline of 24.9% from the November 30th total of 22,500 shares. Based on an average daily volume of 29,300 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.1% of the shares of the stock are short sold.

vTv Therapeutics Price Performance

Shares of VTVT opened at $13.20 on Friday. The company has a market capitalization of $42.11 million, a price-to-earnings ratio of -2.91 and a beta of 0.67. The business’s 50-day moving average is $15.02 and its 200-day moving average is $16.05. vTv Therapeutics has a fifty-two week low of $7.38 and a fifty-two week high of $30.99.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners started coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 price target on the stock.

Institutional Investors Weigh In On vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. FMR LLC purchased a new position in vTv Therapeutics Inc. (NASDAQ:VTVT) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned about 5.92% of vTv Therapeutics at the end of the most recent quarter. 17.51% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.